Newborn screening: Complexities in universal genetic testing

American Journal of Public Health

Volumn 96, Issue 11, 2006, Pages 1955-1959

  Green, Nancy S ^a,b   Dolan, Siobhan M ^b   Murray, Thomas H ^c  

^a March of Dimes Birth Defects Foundation   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c HASTINGS CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEDIUM CHAIN ACYL COENZYME A DEHYDROGENASE;

CYSTIC FIBROSIS; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; ENZYME DEFICIENCY; GENETIC ANALYSIS; HUMAN; MEDIUM CHAIN ACYL COENZYME A DEHYDROGENASE DEFICIENCY; METABOLIC DISORDER; NEWBORN; NEWBORN SCREENING; PHENYLKETONURIA; REVIEW; SOCIAL ASPECT; TECHNOLOGY;

ACYL-COA DEHYDROGENASE; ADRENAL HYPERPLASIA, CONGENITAL; CULTURAL DIVERSITY; CYSTIC FIBROSIS; EARLY DIAGNOSIS; GENETIC SCREENING; HUMANS; INFANT, NEWBORN; MANDATORY TESTING; METABOLISM, INBORN ERRORS; NEONATAL SCREENING; PHENYLKETONURIAS; POLITICS; PUBLIC HEALTH ADMINISTRATION; SOCIAL JUSTICE;

EID: 33750493316     PISSN: 00900036     EISSN: None     Source Type: Journal    
DOI: 10.2105/AJPH.2005.070300     Document Type: Review

References (42)

1. Newborn Screening: Characteristics of State Programs. Washington, DC: US General Accounting Office; 2003:1-47. Publication GAO-03-449.
2. Therrell BL. US newborn screening policy dilemmas for the twenty-first century. Mol Genet Metab. 2001;74:64-72.
3. Schulze A, Lindner M, Kohlmuller D, Olgemoller K, Mayatepek E, Hoffmann GF. Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry: results, outcome, and implications. Pediatrics. 2003;111:1399-1406.
4. National Institutes of Health Consensus Development Conference Statement: phenylketonuria: screening and management, October 16-18, 2000. Pediatrics. 2001;108:972-982.
5. Healthy Children: Investing in the Future. Washington, DC: US Congress, Office of Technology Assessment; 1988. Publication OTA-H-345.
6. Serving the family from birth to the medical home. Newborn screening: a blueprint for the future - a call for a national agenda on state newborn screening programs. AAP Newborn Screening Task Force. Pediatrics. 2000;106:383-422.
7. Paul DB. The history of newborn phenylketonuria screening in the US. In: Holzman NA, Watson MS, eds. Promoting Safe and Effective Genetic Testing in the United States: Final Report of the Task Force on Genetic Testing. Bethesda, Md: National Institutes of Health; 1997: 137-160.
8. Watson M, Puryear M. Newborn Screening: Toward a Uniform Screening Panel and System [summary]. Pediatrics. In press.
9. National Newborn Screening and Genetics Resource Center. National Newborn Screening Status Report. Available at: http://genes-r-us.uthscsa.edu/ nbsdisorders.pdf. Accessed September 15, 2005.
10. Governor Announces Historic Expansion of Newborn Screening [10/27/04]. Available at: http://www. huntershope.org/news/press_releases/albany_nbs_pr.asp. Accessed January 19, 2006.
11. Burke W, Atkins D, Gwinn M, et al. Genetic test evaluation: information needs of clinicians, policy makers, and the public. Am J Epidemiol. 2002;156:311-318.
12. Natowicz M. Newborn screening-setting evidence-based policy for protection. N Engl J Med. 2005;353:867-870.
13. Botkin JR, Clayton EW, Post NC, et al. Comment on a report of the American College of Medical Genetics report titled Newborn Screening: toward a uniform screening panel and system. Pediatrics. In press.
14. Title XXVI of the Children's Health Act of 2000, Screening for Heritable Disorders, 42 USC §300b-10.
15. Green NS, Pass KA. Neonatal screening by DNA microarray: spots and chips. Nat Rev Genet. 2005;6:147-151.
16. Millner BN. Insurance coverage of special foods needed in the treatment of phenylketonuria. Public Health Rep. 1993;108:60-65.
17. Brown AS, Fernhoff PM, Waisbren SE, et al. Barriers to successful dietary control among pregnant women with phenylketonuria. Genet Med. 2002;4:84-89.
18. Centers for Disease Control and Prevention. Barriers to dietary control among pregnant women with phenylketonuria-United States, 1998-2000. MMWR Morb Mortal Wkly Rep. 2002;51:117-120.
19. Wang SS, Fernhoff PM, Hannon WH, Khoury MJ. Medium chain acyl-CoA dehydrogenase deficiency human genome epidemiology review. Genet Med. 1999;1:332-339.
20. Pourfarzam M, Morris A, Appleton M, Craft A, Bartlett K. Neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency. Lancet. 2001;358:1063-1064.
21. Carpenter K, Wiley V, Sim KG, Heath D, Wilcken B. Evaluation of newborn screening for medium chain acyl-CoA dehydrogenase deficiency in 275000 babies. Arch Dis Child Fetal Neonatal Ed. 2001;85:F105-F1099.
22. Waisbren SE, Albers S, Amato S, et al. Effect of expanded newborn screening for biochemical genetic disorders on child outcomes and parental stress. JAMA. 2003;290:2564-2572.
23. Atkinson K, Zuckerman B, Sharfstein JM, Levin D, Blatt RJ, Koh HK. A public health response to emerging technology: expansion of the Massachusetts newborn screening program. Public Health Rep. 2001;116:122-131.
24. Holtzman NA. Expanding newborn screening: how good is the evidence? JAMA. 2003;290:2606-2608.
25. Ratjen F, Doring G. Cystic fibrosis. Lancet. 2003;361:681-689.
26. Green NS, Dolan SM, Oinuma M. Implementation of newborn screening for cystic fibrosis varies widely between states. Pediatrics. 2004;114:515-516.
27. Gregg RG, Simantel A, Farrell PM, et al. Newborn screening for cystic fibrosis in Wisconsin: comparison of biochemical and molecular methods. Pediatrics. 1997;99:819-824.
28. Comeau AM, Parad RB, Dorkin HL, et al. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections. Pediatrics. 2004;113: 1573-1581.
29. The American College of Obstetricians and Gynecologists and American College of Medical Genetics. Preconception and Prenatal Carrier Screening for Cystic Fibrosis: Clinical and Laboratory Guidelines. Washington, DC: American College of Obstetricians and Gynecologists; 2001.
30. Grosse SD, Boyle CA, Botkin JR, et al. Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Morbid Mortal Wkly Rep. 2004;53(RR-13):1-36.
31. Farrell PM, Kosorok MR, Rock MJ, et al. Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. Pediatrics. 2001;107:1-13.
32. Farrell PM, Li Z, Kosorok MR, et al. Bronchopulmonary disease in children with cystic fibrosis after early or delayed diagnosis. Am J Respir Crit Care Med. 2003;168:1100-1108.
33. Clayton EW. What should be the role of public health in newborn screening and prenatal diagnosis? Am J Prev Med. 1999;16:111-115.
34. Oliver S, Dezateux C, Kavanagh J, Lempert T, Stewart R. Disclosing to parents newborn carrier status identified by routine blood spot screening. Cochrane Database Syst Rev. October 2004:CD003859.
35. Kladny B, Gettig EA, Krishnamurti L. Systematic follow-up and case management of the abnormal newborn screen can improve acceptance of genetic counseling for sickle cell or other hemoglobinopathy trait. Genet Med. 2005;7:139-142.
36. Lindegren ML, Kobrinksi L, Rasmussen S, et al. Applying public health strategies to primary immunodeficiency diseases: a potential approach to genetic disorders. MMWR Morb Mortal Wkly Rep. 2004;53(RR-1):1-29.
37. Meikle PJ, Ranieri E, Simonsen H, et al. Newborn screening for lysosomal storage disorders: clinical evaluation of a two-tier strategy. Pediatrics. 2004;114:909-916.
38. Merikangas KR, Risch N. Genomic priorities and public health. Science. 2003;302:599-601.
39. Levy HL. Lessons from the past-looking to the future. Newborn screening. Pediatr Ann. 2003;32:505-508.
40. Wion E, Brantley M, Stevens J, et al. Population-wide infant screening for HLA-based type 1 diabetes risk via dried blood spots from the public health infrastructure. Ann N Y Acad Sci. 2003; 1005:400-403.
41. Ross LF. Minimizing risks: the ethics of predictive diabetes mellitus screening research in newborns. Arch Pediatr Adolesc Med. 2003;157:89-95.
42. Finley Austin MJ, Kreiner T. Integrating genomics technologies in health care: practice and policy challenges and opportunities. Physiol Genomics. 2002;8:33-40.